drugset / Trial / NCT03448172

Single-dose Study of [14C]PF-05221304 Metabolism and Excretion in Healthy Adult Male Subjects

NCT03448172

Phase 1 Completed 6 enrolled Pfizer
Non-randomizedSingle-groupOpen-labelBasic science

Summary

The purpose of the study is to characterize the absorption, distribution, metabolism, and excretion (ADME) of a single oral dose of \[14C\]PF-05221304 in Healthy Adult Male Subjects

Timeline

Start
2018-04-18
Primary completion
2018-05-26
Completion
2018-06-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Clesacostat Small molecule 50 mg Oral

Indications

No indication recorded.